Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) - Net Assets
Based on the latest financial reports, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has net assets worth CN¥1.60 Billion CNY (≈ $234.60 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.39 Billion ≈ $935.45 Million USD) and total liabilities (CN¥4.79 Billion ≈ $700.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Hunan Dajiaweikang Pharmaceutical Indust to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.60 Billion |
| % of Total Assets | 25.08% |
| Annual Growth Rate | 8.48% |
| 5-Year Change | -5.13% |
| 10-Year Change | N/A |
| Growth Volatility | 23.76 |
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's net assets have evolved over time, based on quarterly financial data. See 301126 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2025)
The table below shows the annual net assets of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2025. For live valuation and market cap data, see 301126 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.59 Billion ≈ $233.10 Million |
-13.83% |
| 2024-12-31 | CN¥1.85 Billion ≈ $270.52 Million |
+3.76% |
| 2023-12-31 | CN¥1.78 Billion ≈ $260.71 Million |
-1.96% |
| 2022-12-31 | CN¥1.82 Billion ≈ $265.92 Million |
+8.22% |
| 2021-12-31 | CN¥1.68 Billion ≈ $245.71 Million |
+61.24% |
| 2020-12-31 | CN¥1.04 Billion ≈ $152.39 Million |
+6.57% |
| 2019-12-31 | CN¥977.24 Million ≈ $143.00 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥296.58 Million | 19.93% |
| Other Components | CN¥1.19 Billion | 80.07% |
| Total Equity | CN¥1.49 Billion | 100.00% |
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Competitors by Market Cap
The table below lists competitors of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jouder Precision Industry Kunshan Co Ltd
SHE:300549
|
$278.63 Million |
|
Nano Dimension Ltd
NASDAQ:NNDM
|
$278.70 Million |
|
Baiyang Aquatic Group Inc
SHE:002696
|
$278.78 Million |
|
American Bitcoin Corp
NASDAQ:ABTC
|
$278.79 Million |
|
Papercorea
KO:001020
|
$278.53 Million |
|
Shanghai Kaytune Industrial Co.Ltd
SHE:301001
|
$278.38 Million |
|
Ressources Minieres Radisson Inc
V:RDS
|
$278.33 Million |
|
Keysino Separation Technology Inc
SHE:300899
|
$278.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,756,782,100 to 1,487,864,127, a change of -268,917,972 (-15.3%).
- Net loss of 242,458,514 reduced equity.
- Dividend payments of 111,992,906 reduced retained earnings.
- Other factors increased equity by 85,533,448.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-242.46 Million | -16.3% |
| Dividends Paid | CN¥111.99 Million | -7.53% |
| Other Changes | CN¥85.53 Million | +5.75% |
| Total Change | CN¥- | -15.31% |
Book Value vs Market Value Analysis
This analysis compares Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.47x to 1.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥6.31 | CN¥9.27 | x |
| 2020-12-31 | CN¥6.72 | CN¥9.27 | x |
| 2021-12-31 | CN¥8.13 | CN¥9.27 | x |
| 2022-12-31 | CN¥8.34 | CN¥9.27 | x |
| 2023-12-31 | CN¥8.46 | CN¥9.27 | x |
| 2024-12-31 | CN¥8.55 | CN¥9.27 | x |
| 2025-12-31 | CN¥7.24 | CN¥9.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.71%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 4.26x
- Recent ROE (-16.30%) is below the historical average (1.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 8.97% | 3.57% | 1.22x | 2.06x | CN¥-10.07 Million |
| 2020 | 6.23% | 2.77% | 1.06x | 2.11x | CN¥-39.29 Million |
| 2021 | 4.07% | 2.63% | 0.87x | 1.78x | CN¥-99.66 Million |
| 2022 | 2.97% | 1.55% | 0.84x | 2.28x | CN¥-121.16 Million |
| 2023 | 1.96% | 0.88% | 0.74x | 3.02x | CN¥-140.42 Million |
| 2024 | 1.51% | 0.51% | 0.85x | 3.52x | CN¥-149.10 Million |
| 2025 | -16.30% | -4.71% | 0.81x | 4.26x | CN¥-391.24 Million |
Industry Comparison
This section compares Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $3,300,392,540
- Average return on equity (ROE) among peers: 12.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | CN¥1.60 Billion | 8.97% | 2.99x | $278.63 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $5.92 Billion | 5.01% | 1.80x | $572.42 Million |
| Yunnan Hongxiang Yixintang (002727) | $810.77 Million | 22.52% | 0.88x | $922.05 Million |
| Luyan Pharma Co Ltd (002788) | $3.32 Billion | 8.45% | 3.03x | $622.53 Million |
| Ji Yao Holding Group Co Ltd (300108) | $58.56 Million | 22.82% | 0.31x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $1.91 Billion | 6.00% | 1.61x | $795.33 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $2.06 Billion | 6.68% | 1.34x | $896.74 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $186.74 Million | 13.27% | 2.88x | $317.63 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $8.14 Billion | 11.24% | 2.25x | $2.68 Billion |
| Laobaixing Pharmacy (603883) | $7.29 Billion | 12.75% | 1.91x | $1.31 Billion |
About Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages… Read more